Stockscreener 앱 받기
0.661
5.93%
0.037
시간 외 거래:
.66
-0.001
-0.15%
전일 마감가:
$0.624
열려 있는:
$0.6115
하루 거래량:
399.73K
Relative Volume:
0.37
시가총액:
$9.52M
수익:
-
순이익/손실:
$-20.87M
주가수익비율:
-0.4151
EPS:
-1.5924
순현금흐름:
$-21.21M
1주 성능:
+19.75%
1개월 성능:
+8.20%
6개월 성능:
-78.54%
1년 성능:
-68.97%
1일 변동 폭
$0.60
$0.6763
1주일 범위
$0.4606
$0.6932
52주 변동 폭
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
명칭
Calcimedica Inc
전화
858-952-5500
주소
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.661 | 8.99M | 0 | -20.87M | -21.21M | -1.5924 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc 주식(CALC)의 최신 뉴스
Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating - marketscreener.com
CalciMedica price target lowered to $10 from $20 at Oppenheimer - TipRanks
CALC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Calcimedica Inc files for mixed shelf of up to $125 millionSEC filing - marketscreener.com
Calcimedica Inc Files For Mixed Shelf Of Up To $125 MillionSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files shelf to offer up to $125M in securities - Stock Titan
CalciMedica (NASDAQ: CALC) outlines Auxora pipeline, halted AKI trial and going concern risk - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CALCForm 8-KCurrent report - ADVFN Ltd
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PR Newswire
Retail Trends: Whats next for CalciMedica Inc stock2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
CALC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CALC SEC FilingsCALCIMEDICA INC 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Vistagen Therapeutics Inc. stock a top pick in earnings seasonGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Does CalciMedica Inc. meet Warren Buffett’s criteria2025 Stock Rankings & Weekly High Conviction Ideas - mfd.ru
Should I set a stop loss on CalciMedica Inc.July 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Aug Highlights: What’s the fair value of DUK.PRA stockQuarterly Trade Review & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Earnings Risk: Does CalciMedica Inc meet Warren Buffetts criteria2025 Price Momentum & Technical Pattern Recognition Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
How Is The Market Feeling About CalciMedica Inc? - Benzinga
What is CalciMedica Inc.’s book value per shareWeekly Trend Summary & AI Enhanced Trading Signals - mfd.ru
CalciMedica downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
CalciMedica Shares Plunge After Discontinuing Phase II AKI Study - Citeline News & Insights
CalciMedica stock downgraded to Neutral by H.C. Wainwright after trial halt - Investing.com Canada
CalciMedica’s stock drops 75% on acute kidney injury trial termination - Clinical Trials Arena
CALC Stock Slumped 76% On Wednesday — Here’s Why - Asianet Newsable
CalciMedica discontinues AKI trial following safety concerns By Investing.com - Investing.com South Africa
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation By Investing.com - Investing.com Nigeria
CalciMedica Discontinues Trial, Stock Faces Volatility - intellectia.ai
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation - Investing.com
Calcimedica Discontinues Phase 2 Kourage Trial - TradingView
CalciMedica Ends KOURAGE Trial, Extends Cash Runway - TipRanks
Sector Update: Health Care - marketscreener.com
CalciMedica oversold on KOURAGE news, says Oppenheimer - TipRanks
CalciMedica ( CALC) Stock: Stops Phase 2 KOURAGE trial amid Enrollment Criteria Concerns - parameter.io
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Gold Jumps Over 4%; Seagate Shares Gain After Q2 Results - Benzinga
Calcimedica sags on halt of Auxora trial in acute kidney injury - bioworld.com
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis - Benzinga
CalciMedica Shares Hit 52-Week Low After Ending Auxora Trial - marketscreener.com
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales - Benzinga
CalciMedica stock craters as trial stopped over 'safety concern' - Fierce Biotech
CalciMedica tumbles as safety concerns halt trial of kidney injury drug - TradingView
CalciMedica stock plunges after discontinuing kidney injury trial By Investing.com - Investing.com Australia
CalciMedica stock plunges after discontinuing kidney injury trial - Investing.com
CalciMedica Halts Phase 2 KOURAGE Trial After Safety Review - TipRanks
CalciMedica discontinues AKI trial following safety concerns - Investing.com
CalciMedica announces discontinuation of Phase 2 KOURAGE clinical trial - TipRanks
CalciMedica Inc Discontinues Phase 2 KOURAGE Trial - TradingView
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation - PR Newswire
Calcimedica Inc (CALC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):